This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Tumour Impact

The majority of pituitary tumours remain stable with Somavert1

  • Treatment-resistant tumour progression occurs in a small minority of patients with acromegaly, regardless of treatment modality2
  • When no tumour growth is observed in the first 18 months of treatment with Somavert,it is unlikely that any growth will occur subsequently3​​​​​​​
  • As growth hormone-secreting pituitary tumours may sometimes expand, causing serious complications (e.g. visual field defects), it is essential that all patients be carefully monitored. If evidence of tumour expansion appears, alternative procedures may be advisable. 
​​​​​​​​​​​​​​

A proportion of patients from Fleserui1 were anaylsed, looking at tumour stability:

 
- 2162 patients analysed for pituitary imaging
- 1795 patients had ≥1 pituitary imaging result
- 1276 (71.1%) patients had no change in pituitary tumour size, relative to their last examination based on local assessment 
- 519 patients with a change in pituitary tumour size detected by local assessment: 128 (7.1%) with an increase only; 310 (17.3%) with a decrease only; and 81 (4.5%) with both an increase & decrease (observed at different timepoints).
- 264 out of the 1795 patients had MRI results assessed centrally which showed tumour volume increases in 54 (3.0%); decreases in 84 (4.7%); both increases & decreases in 12 (0.7%); no change in - 74 (4.1%) and insufficient data in 40 (2.2%)
- Changes in pituitary tumour size were reported as AEs of special interest in 96 (4.3%) of cases (24 (1.1%) considered treatment related) and caused 31 (1.4%) patients to discontinue pegvisomant treatment.1

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

** This is an optional area where footnotes can live.

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

References 

1. M Fleseriu, et al. Eur J Endocrinol. 2021 Aug 27;185(4):525-538
2. Besser GM et al. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005;153:187–93.
3. Jiminez et al., Follow-up of pituitary tumour volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008: 159(5): 517–23.

PP-SOM-GBR-1122. January 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?